GSK PLC-SPON ADR (GSK) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:GSK • US37733W2044

52.9 USD
+0.43 (+0.82%)
Last: Feb 3, 2026, 12:34 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to GSK. GSK was compared to 191 industry peers in the Pharmaceuticals industry. While GSK has a great profitability rating, there are some minor concerns on its financial health. GSK is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year GSK was profitable.
  • In the past year GSK had a positive cash flow from operations.
  • In the past 5 years GSK has always been profitable.
  • Each year in the past 5 years GSK had a positive operating cash flow.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

1.2 Ratios

  • The Return On Assets of GSK (8.96%) is better than 91.10% of its industry peers.
  • GSK's Return On Equity of 34.02% is amongst the best of the industry. GSK outperforms 95.29% of its industry peers.
  • GSK has a Return On Invested Capital of 18.16%. This is amongst the best in the industry. GSK outperforms 95.29% of its industry peers.
  • GSK had an Average Return On Invested Capital over the past 3 years of 18.38%. This is significantly above the industry average of 12.82%.
Industry RankSector Rank
ROA 8.96%
ROE 34.02%
ROIC 18.16%
ROA(3y)12.52%
ROA(5y)10.05%
ROE(3y)65.63%
ROE(5y)53.08%
ROIC(3y)18.38%
ROIC(5y)14.53%
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • GSK's Profit Margin of 17.08% is amongst the best of the industry. GSK outperforms 89.53% of its industry peers.
  • GSK's Profit Margin has declined in the last couple of years.
  • GSK has a Operating Margin of 26.20%. This is amongst the best in the industry. GSK outperforms 92.15% of its industry peers.
  • GSK's Operating Margin has been stable in the last couple of years.
  • GSK has a Gross Margin of 72.52%. This is amongst the best in the industry. GSK outperforms 80.10% of its industry peers.
  • GSK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 26.2%
PM (TTM) 17.08%
GM 72.52%
OM growth 3Y3.67%
OM growth 5Y-0.3%
PM growth 3Y-22.68%
PM growth 5Y-9.82%
GM growth 3Y2.09%
GM growth 5Y0.57%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GSK is creating value.
  • Compared to 1 year ago, GSK has more shares outstanding
  • GSK has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for GSK has been reduced compared to a year ago.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • GSK has an Altman-Z score of 2.20. This is not the best score and indicates that GSK is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.20, GSK is doing good in the industry, outperforming 61.26% of the companies in the same industry.
  • GSK has a debt to FCF ratio of 3.78. This is a good value and a sign of high solvency as GSK would need 3.78 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.78, GSK belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
  • A Debt/Equity ratio of 0.92 indicates that GSK is somewhat dependend on debt financing.
  • GSK has a Debt to Equity ratio of 0.92. This is in the lower half of the industry: GSK underperforms 72.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF 3.78
Altman-Z 2.2
ROIC/WACC2.08
WACC8.75%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.84 indicates that GSK may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.84, GSK is doing worse than 87.96% of the companies in the same industry.
  • GSK has a Quick Ratio of 0.84. This is a bad value and indicates that GSK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GSK has a worse Quick ratio (0.55) than 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.55
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

4

3. Growth

3.1 Past

  • GSK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.73%.
  • The Earnings Per Share has been growing slightly by 0.56% on average over the past years.
  • Looking at the last year, GSK shows a small growth in Revenue. The Revenue has grown by 2.73% in the last year.
  • GSK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.45% yearly.
EPS 1Y (TTM)2.73%
EPS 3Y4.05%
EPS 5Y0.56%
EPS Q2Q%10.66%
Revenue 1Y (TTM)2.73%
Revenue growth 3Y8.31%
Revenue growth 5Y-1.45%
Sales Q2Q%6.68%

3.2 Future

  • Based on estimates for the next years, GSK will show a small growth in Earnings Per Share. The EPS will grow by 7.25% on average per year.
  • Based on estimates for the next years, GSK will show a small growth in Revenue. The Revenue will grow by 3.96% on average per year.
EPS Next Y8.35%
EPS Next 2Y8.33%
EPS Next 3Y8.41%
EPS Next 5Y7.25%
Revenue Next Year4.28%
Revenue Next 2Y4.69%
Revenue Next 3Y4.66%
Revenue Next 5Y3.96%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.21 indicates a reasonable valuation of GSK.
  • Compared to the rest of the industry, the Price/Earnings ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 90.05% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of GSK to the average of the S&P500 Index (28.41), we can say GSK is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 10.17, the valuation of GSK can be described as reasonable.
  • 86.91% of the companies in the same industry are more expensive than GSK, based on the Price/Forward Earnings ratio.
  • GSK's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.64.
Industry RankSector Rank
PE 11.21
Fwd PE 10.17
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GSK is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 87.43% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 16.61
EV/EBITDA 7.67
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.34
PEG (5Y)19.96
EPS Next 2Y8.33%
EPS Next 3Y8.41%

More info and screens

5

5. Dividend

5.1 Amount

  • GSK has a Yearly Dividend Yield of 3.46%. Purely for dividend investing, there may be better candidates out there.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 0.62. GSK pays more dividend than 95.29% of the companies in the same industry.
  • GSK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
Industry RankSector Rank
Dividend Yield 3.46%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • GSK has decreased its dividend recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

  • 46.05% of the earnings are spent on dividend by GSK. This is a bit on the high side, but may be sustainable.
DP46.05%
EPS Next 2Y8.33%
EPS Next 3Y8.41%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

GSK PLC-SPON ADR

NYSE:GSK (2/3/2026, 12:34:02 PM)

52.9

+0.43 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-29
Earnings (Next)02-04
Inst Owners43.55%
Inst Owner Change204.24%
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap106.70B
Revenue(TTM)32.17B
Net Income(TTM)5.49B
Analysts70.97
Price Target50.54 (-4.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.46%
Yearly Dividend1.67
Dividend Growth(5Y)-9.84%
DP46.05%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.24%
Min EPS beat(2)7.67%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)12.2%
Min EPS beat(4)7.67%
Max EPS beat(4)18.46%
EPS beat(8)7
Avg EPS beat(8)10.47%
EPS beat(12)11
Avg EPS beat(12)9.92%
EPS beat(16)15
Avg EPS beat(16)9.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)-0.04%
Revenue beat(4)1
Avg Revenue beat(4)-0.06%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)1.68%
Revenue beat(8)4
Avg Revenue beat(8)0.89%
Revenue beat(12)7
Avg Revenue beat(12)1.15%
Revenue beat(16)9
Avg Revenue beat(16)-1.83%
PT rev (1m)1.93%
PT rev (3m)12.32%
EPS NQ rev (1m)-2.77%
EPS NQ rev (3m)-6.08%
EPS NY rev (1m)0.81%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)2.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE 11.21
Fwd PE 10.17
P/S 2.43
P/FCF 16.61
P/OCF 10.01
P/B 4.83
P/tB N/A
EV/EBITDA 7.67
EPS(TTM)4.72
EY8.92%
EPS(NY)5.2
Fwd EY9.83%
FCF(TTM)3.18
FCFY6.02%
OCF(TTM)5.28
OCFY9.99%
SpS21.81
BVpS10.95
TBVpS-5.31
PEG (NY)1.34
PEG (5Y)19.96
Graham Number34.1
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 34.02%
ROCE 21.06%
ROIC 18.16%
ROICexc 19.79%
ROICexgc 57.12%
OM 26.2%
PM (TTM) 17.08%
GM 72.52%
FCFM 14.6%
ROA(3y)12.52%
ROA(5y)10.05%
ROE(3y)65.63%
ROE(5y)53.08%
ROIC(3y)18.38%
ROIC(5y)14.53%
ROICexc(3y)22.56%
ROICexc(5y)17.82%
ROICexgc(3y)78.4%
ROICexgc(5y)77.5%
ROCE(3y)21.97%
ROCE(5y)17.32%
ROICexgc growth 3Y-7.02%
ROICexgc growth 5Y-6.42%
ROICexc growth 3Y24.64%
ROICexc growth 5Y6.13%
OM growth 3Y3.67%
OM growth 5Y-0.3%
PM growth 3Y-22.68%
PM growth 5Y-9.82%
GM growth 3Y2.09%
GM growth 5Y0.57%
F-Score7
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF 3.78
Debt/EBITDA 1.24
Cap/Depr 87.43%
Cap/Sales 9.62%
Interest Coverage 13.36
Cash Conversion 65.11%
Profit Quality 85.49%
Current Ratio 0.84
Quick Ratio 0.55
Altman-Z 2.2
F-Score7
WACC8.75%
ROIC/WACC2.08
Cap/Depr(3y)108.08%
Cap/Depr(5y)108.56%
Cap/Sales(3y)8.31%
Cap/Sales(5y)9.2%
Profit Quality(3y)87.63%
Profit Quality(5y)97.06%
High Growth Momentum
Growth
EPS 1Y (TTM)2.73%
EPS 3Y4.05%
EPS 5Y0.56%
EPS Q2Q%10.66%
EPS Next Y8.35%
EPS Next 2Y8.33%
EPS Next 3Y8.41%
EPS Next 5Y7.25%
Revenue 1Y (TTM)2.73%
Revenue growth 3Y8.31%
Revenue growth 5Y-1.45%
Sales Q2Q%6.68%
Revenue Next Year4.28%
Revenue Next 2Y4.69%
Revenue Next 3Y4.66%
Revenue Next 5Y3.96%
EBIT growth 1Y6.52%
EBIT growth 3Y12.28%
EBIT growth 5Y-1.74%
EBIT Next Year30.51%
EBIT Next 3Y13.68%
EBIT Next 5Y9.82%
FCF growth 1Y48.4%
FCF growth 3Y-10.73%
FCF growth 5Y-9.42%
OCF growth 1Y42.27%
OCF growth 3Y-6.24%
OCF growth 5Y-3.96%

GSK PLC-SPON ADR / GSK FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.35% in the next year.